Kaitlyn Bader

1 week ago | dermatologytimes.com | Kaitlyn Bader

The US FDA has extended the review period of Incyte’s supplemental New Drug Application (sNDA) for ruxolitinib (Opzelura) cream for the treatment of pediatric patients aged 2 to 11 years with mild to moderate atopic dermatitis (AD).

1 week ago | dermatologytimes.com | Anabela Cardoso |Kaitlyn Bader

At the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee, Eli Lilly and Company presented new data from the phase 3b ADmirable trial (NCT05372419) of lebrikizumab (Ebglyss).1 The study is the first to evaluate lebrikizumab’s effectiveness and safety in adult and adolescent patients with pigmented skin and atopic dermatitis, as this population is typically underrepresented in clinical trials.

1 week ago | dermatologytimes.com | Kaitlyn Bader

To stay informed with all conference insights, subscribe to receive our eNewsletters. Catch up on what to expect at this year's RAD conference in Nashville, Tennessee. Discover the latest breakthroughs in atopic dermatitis treatment and expert insights from the RAD dermatology conference in Nashville. Arcutis Biotherapeutics showcases promising long-term results of Zoryve for atopic dermatitis in young children at RAD 2025, emphasizing safety and efficacy.

2 weeks ago | dermatologytimes.com | Matthew Zirwas |Kaitlyn Bader

“If tofacitinib as a generic is easily accessible as something we can just write and people get it without a prior authorization, it's hard to describe how much that could revolutionize dermatology. It might actually be the end of prednisone,” said Matthew Zirwas, MD, in an interview with Dermatology Times.

2 weeks ago | dermatologytimes.com | Matthew Zirwas |Kaitlyn Bader

“Nemolizumab is a drug that we really should be thinking about in our patients who are particularly itchy and are willing to wait longer for the rash to get better, or willing to maybe not have the rash ever get quite as good as it could if we blocked IL-13 instead. But we don’t have any answer. We won’t have an answer unless we get a head-to-head trial,” said Matthew Zirwas, MD, in an interview with Dermatology Times.